Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.38 |
| ▸ | FDPS | P14324 | 10/20 | 0.36 |
| ▸ | GGPS1 | O95749 | 6/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18421819 | 0.87 | ESR1 (0.34) | ESR1ESR2FDPSGGPS1 | |
| SCHEMBL1832910 | 0.85 | AKR1B1 (0.37) | ESR1ALDH1A1TSHR | |
| SCHEMBL3827161 | 0.84 | FDPS (0.39) | FDPSALDH1A1 | |
| SCHEMBL2349836 | 0.79 | ESR1 (0.39) | ESR1ESR2FDPSGGPS1ALDH1A1 | |
| SCHEMBL14844470 | 0.77 | ESR1 (0.38) | ESR1ESR2FDPSGGPS1ALDH1A1 | |
| SCHEMBL28642670 | 0.77 | ESR1 (0.38) | ESR1ESR2FDPSGGPS1ALDH1A1 | |
| SCHEMBL21086309 | 0.77 | ESR1 (0.38) | ESR1ESR2FDPSGGPS1ALDH1A1 | |
| SCHEMBL2358431 | 0.76 | FDPS (0.45) | ESR1FDPSGGPS1ALDH1A1TSHR | |
| SCHEMBL10619531 | 0.76 | AKR1B1 (0.34) | ESR1FDPSGGPS1ALDH1A1TSHR | |
| SCHEMBL7172289 | 0.76 | FDPS (0.45) | ESR1FDPSGGPS1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021451-B2 | Contrast agents | BRACCO IMAGING S.P.A. (IT) | 2021-06-01 | — | — | US | disclosed |
| EP-3386953-B1 | CONTRAST AGENTS | BRACCO IMAGING SPA (IT) | 2020-10-21 | — | — | EP | disclosed |
| US-20200325108-A1 | CONTRAST AGENTS | BRACCO IMAGING S.P.A. (IT) | 2020-10-15 | — | — | US | disclosed |
| US-10781188-B2 | Contrast agents | BRACCO IMAGING S.P.A. (IT) | 2020-09-22 | — | — | US | disclosed |
| US-20180362476-A1 | CONTRAST AGENTS | BRACCO IMAGING S.P.A. (IT) | 2018-12-20 | — | — | US | disclosed |
| EP-3386953-A1 | CONTRAST AGENTS | Bracco Imaging SpA (IT) | 2018-10-17 | — | — | EP | disclosed |
| WO-2017098038-A1 | CONTRAST AGENTS | BRACCO IMAGING SPA (IT) | 2017-06-15 | — | — | WO | disclosed |
| EP-1930338-A1 | Fumaric acid derivates and ophtalmic lenses using the same | E-brain Corporation Ltd. (JP) | 2008-06-11 | — | — | EP | disclosed |
| US-20080132666-A1 | Fumaric Acid Derivatives and Ophthalmic Lenses Using the Same | MENICON NECT CO., LTD. (JP) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132666-A1 | Fumaric Acid Derivatives and Ophthalmic Lenses Using the Same | FAH, FH, AQP4 | ESR1 4045/4885ESR2 4557/4885FDPS 264/4885 |
| US-11021451-B2 | Contrast agents | SLC39A14, ABCB7, SLC40A1 | ESR1 4134/4885ESR2 3040/4885FDPS 3333/4885 |
| US-20200325108-A1 | CONTRAST AGENTS | SLC39A14, ABCB7, SLC40A1 | ESR1 4134/4885ESR2 3040/4885FDPS 3333/4885 |
| US-20180362476-A1 | CONTRAST AGENTS | SLC30A5, SLC39A14, ABCB7 | ESR1 4175/4885ESR2 3003/4885FDPS 3443/4885 |
| US-10781188-B2 | Contrast agents | SLC39A14, ABCB7, SLC40A1 | ESR1 4134/4885ESR2 3040/4885FDPS 3333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.